RAFAEL HOLDINGS, INC. Finance Lease, Impairment Loss
RAFAEL HOLDINGS, INC. (RFL) reported Finance Lease, Impairment Loss of $17.30 million for the 12-month period ending 2023-07-31, per its 10-K filed 2023-10-30.
Discontinued › Expense Statement › Operating Expenses
us-gaap:FinanceLeaseImpairmentLoss · last filed 2023-10-30
- RAFAEL HOLDINGS, INC. finance lease, impairment loss for the quarter ending 2023-07-31 was $0.00.
- RAFAEL HOLDINGS, INC. finance lease, impairment loss for the quarter ending 2023-04-30 was $0.00.
- RAFAEL HOLDINGS, INC. finance lease, impairment loss for the quarter ending 2023-01-31 was $0.00.
- RAFAEL HOLDINGS, INC. finance lease, impairment loss for the quarter ending 2022-10-31 was $17.30M, a 0.00% change year-over-year.
- RAFAEL HOLDINGS, INC. finance lease, impairment loss for fiscal 2023 was $17.30M, a 0.00% change from fiscal 2022.
- RAFAEL HOLDINGS, INC. finance lease, impairment loss for fiscal 2022 was $17.30M.
| Period end | Finance Lease, Impairment Loss 3 month | Finance Lease, Impairment Loss 6 month | Finance Lease, Impairment Loss 9 month | Finance Lease, Impairment Loss 12 month |
|---|---|---|---|---|
| 2023-07-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-30 | $0.00 derived: sum of 2 quarters · filed 2023-10-30 | $0.00 derived: sum of 3 quarters · filed 2023-10-30 | $17.30M 10-K · filed 2023-10-30 |
| 2023-04-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-06-13 | $0.00 derived: sum of 2 quarters · filed 2023-06-13 | $17.30M 10-Q · filed 2023-06-13 | $17.30M derived: sum of 4 quarters · filed 2023-06-13 |
| 2023-01-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-03-14 | $17.30M 10-Q · filed 2023-03-14 | $17.30M derived: sum of 3 quarters · filed 2023-03-14 | $17.30M derived: sum of 4 quarters · filed 2023-03-14 |
| 2022-10-31 | $17.30M 10-Q · filed 2022-12-13 | $17.30M derived: sum of 2 quarters · filed 2022-12-13 | $17.30M derived: sum of 3 quarters · filed 2022-12-13 | $17.30M derived: sum of 4 quarters · filed 2022-12-13 |
| 2022-07-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-10-31 | $0.00 derived: sum of 2 quarters · filed 2022-10-31 | $0.00 derived: sum of 3 quarters · filed 2022-10-31 | $17.30M 10-K · filed 2022-10-31 |
| 2022-04-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-06-14 | $0.00 derived: sum of 2 quarters · filed 2022-06-14 | $17.30M 10-Q · filed 2022-06-14 | |
| 2022-01-31 | $0.00 derived: 10-Q 6 month − 10-Q/A 3 month · filed 2022-03-17 | $17.30M 10-Q · filed 2022-03-17 | ||
| 2021-10-31 | $17.30M 10-Q/A · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |